Annovis’s Buntanetap Improves Unified Parkinson's Disease Rating Scale and Cognitive Function

Annovis’s Buntanetap Improves Unified Parkinson's Disease Rating Scale and Cognitive Function

By, Admin 4 July 2024

Annovis Bio's Phase III Study Shows Buntanetap Improves Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognitive Function

Overview

Annovis Bio Inc. (NYSE: ANVS) has released new data from its Phase III study of buntanetap, a treatment aimed at neurodegenerative disorders like Parkinson's Disease (PD). The study reveals significant improvements in motor and non-motor functions, as well as cognitive abilities, among patients with early PD. Buntanetap demonstrated the ability to prevent cognitive decline across all enrolled patients, particularly those with mild dementia, where it outperformed the placebo group.

Buntanetap: Effects

  • In patients diagnosed with PD for over three years, buntanetap effectively improved motor functions, as indicated by improvements in MDS-UPDRS Part II, Part III, and Total scores compared to baseline and placebo. 
  • The treatment also showed promise in patients with Postural Instability and Gait Difficulty (PIGD), a subgroup known for rapid disease progression.

Safety Profile of Buntanetap

  • The safety profile of buntanetap was consistent across all participants, reinforcing its safety record from previous AD studies. 
  • These findings underscore Annovis Bio's commitment to advancing buntanetap into further studies to explore its symptomatic benefits and potential disease-modifying properties.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!